References:
1. Lai, C.-C., et al., Asymptomatic carrier state, acute
respiratory disease, and pneumonia due to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of
Microbiology, Immunology and Infection, 2020. 53 (3): p.
404-412.
2. Yu, F., et al., Measures for diagnosing and treating infections
by a novel coronavirus responsible for a pneumonia outbreak originating
in Wuhan, China. Microbes Infect, 2020. 22 (2): p. 74-79.
3. World Health Organization. WHOCoronavirus (COVID-19) dashboard.
Geneva. 2021. Available from: http://covid19.who.int. (Accesses
20th March 2021)
4. Shi, Y., et al., COVID-19 infection: the perspectives on immune
responses. Cell Death & Differentiation, 2020. 27 (5): p.
1451-1454.
5. Bhargava, A., et al., Predictors for Severe COVID-19
Infection. Clin Infect Dis, 2020. 71 (8): p. 1962-1968.
6. Aziz, M., et al., Gastrointestinal predictors of severe
COVID-19: systematic review and meta-analysis. Ann Gastroenterol, 2020.33 (6): p. 615-630.
7. Prompetchara, E., C. Ketloy, and T. Palaga, Immune responses in
COVID-19 and potential vaccines: Lessons learned from SARS and MERS
epidemic. Asian Pac J Allergy Immunol, 2020. 38 (1): p. 1-9.
8. Chen, J., et al., Cellular immune responses to severe acute
respiratory syndrome coronavirus (SARS-CoV) infection in senescent
BALB/c mice: CD4+ T cells are important in control of SARS-CoV
infection. J Virol, 2010. 84 (3): p. 1289-301.
9. Du, R.H., et al., Predictors of mortality for patients with
COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.Eur Respir J, 2020. 55 (5).
10. Urra, J.M., et al., Selective CD8 cell reduction by SARS-CoV-2
is associated with a worse prognosis and systemic inflammation in
COVID-19 patients. Clin Immunol, 2020. 217 : p. 108486.
11. Song, C.-Y., et al., Immune dysfunction following COVID-19,
especially in severe patients. Scientific Reports, 2020.10 (1): p. 15838.
12. Koch, S., et al., Multiparameter flow cytometric analysis of
CD4 and CD8 T cell subsets in young and old people. Immunity & Ageing,
2008. 5 (1): p. 6.
13. Pawelec, G., Age and immunity: What is ”immunosenescence”?Exp Gerontol, 2018. 105 : p. 4-9.
14. Li, H., B. Manwani, and S.X. Leng, Frailty, inflammation, and
immunity. Aging Dis, 2011. 2 (6): p. 466-73.
15. De Biasi, S., et al., Marked T cell activation, senescence,
exhaustion and skewing towards TH17 in patients with COVID-19
pneumonia. Nature Communications, 2020. 11 (1): p. 3434.
16. Kusnadi, A., et al., Severely ill COVID-19 patients display
impaired exhaustion features in SARS-CoV-2-reactive
CD8<sup>+</sup> T cells.Science Immunology, 2021. 6 (55): p. eabe4782.
17. Aalto, H., et al., Monocyte CD14 and soluble CD14 in
predicting mortality of patients with severe community acquired
infection. Scandinavian Journal of Infectious Diseases, 2007.39 (6-7): p. 596-603.
18. Payen, D., et al., A Longitudinal Study of Immune Cells in
Severe COVID-19 Patients. Frontiers in Immunology, 2020.11 (2759).
19. Merah-Mourah, F., et al., Identification of Novel Human
Monocyte Subsets and Evidence for Phenotypic Groups Defined by
Interindividual Variations of Expression of Adhesion Molecules.Scientific Reports, 2020. 10 (1): p. 4397.
20. Wang, Y., et al., Clinical Course and Outcomes of 344
Intensive Care Patients with COVID-19. Am J Respir Crit Care Med, 2020.201 (11): p. 1430-1434.
21. Yang, J., et al., Prevalence of comorbidities and its effects
in patients infected with SARS-CoV-2: a systematic review and
meta-analysis. Int J Infect Dis, 2020. 94 : p. 91-95.
22. Ruan, Q., et al., Clinical predictors of mortality due to
COVID-19 based on an analysis of data of 150 patients from Wuhan,
China. Intensive Care Med, 2020. 46 (5): p. 846-848.
23. Wu, Z. and J.M. McGoogan, Characteristics of and Important
Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China:
Summary of a Report of 72 314 Cases From the Chinese Center for Disease
Control and Prevention. Jama, 2020. 323 (13): p. 1239-1242.
24. Barrett, B., et al., Inflammatory markers are poorly
predictive of clinical outcomes among hospitalized patients with
COVID-19. The American journal of emergency medicine, 2020: p.
S0735-6757(20)31062-7.
25. Okada, R., et al., Phenotypic classification of human CD4+ T
cell subsets and their differentiation. Int Immunol, 2008.20 (9): p. 1189-99.
26. Romero, P., et al., Four Functionally Distinct Populations of
Human Effector-Memory
CD8<sup>+</sup> T
Lymphocytes. The Journal of Immunology, 2007. 178 (7): p.
4112-4119.
27. Amyes, E., A.J. McMichael, and M.F. Callan, Human CD4+ T cells
are predominantly distributed among six phenotypically and functionally
distinct subsets. J Immunol, 2005. 175 (9): p. 5765-73.
28. Kraaijeveld, R., et al., Co-inhibitory profile and
cytotoxicity of CD57(+) PD-1(-) T cells in end-stage renal disease
patients. Clin Exp Immunol, 2018. 191 (3): p. 363-372.
29. Alshekaili, J., et al., STAT3 regulates cytotoxicity of human
CD57+ CD4+ T cells in blood and lymphoid follicles. Scientific Reports,
2018. 8 (1): p. 3529.
30. Cunha, L.L., et al., Remodeling of the Immune Response With
Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune
Response. Frontiers in Immunology, 2020. 11 (1748).
31. Giavridis, T., et al., CAR T cell-induced cytokine release
syndrome is mediated by macrophages and abated by IL-1 blockade. Nat
Med, 2018. 24 (6): p. 731-738.
32. Norelli, M., et al., Monocyte-derived IL-1 and IL-6 are
differentially required for cytokine-release syndrome and neurotoxicity
due to CAR T cells. Nat Med, 2018. 24 (6): p. 739-748.
33. Polilli, E., et al., Comparison of Monocyte Distribution Width
(MDW) and Procalcitonin for early recognition of sepsis. PLoS One,
2020. 15 (1): p. e0227300.
34. Lippi, G. and M. Plebani, The critical role of laboratory
medicine during coronavirus disease 2019 (COVID-19) and other viral
outbreaks. Clin Chem Lab Med, 2020. 58 (7): p. 1063-1069.
35. Sánchez-Cerrillo, I., et al., Differential Redistribution of
Activated Monocyte and Dendritic Cell Subsets to the Lung Associates
with Severity of COVID-19. medRxiv, 2020: p. 2020.05.13.20100925.
36. Khartabil, T.A., et al., A summary of the diagnostic and
prognostic value of hemocytometry markers in COVID-19 patients. Crit
Rev Clin Lab Sci, 2020. 57 (6): p. 415-431.